Biotech Fund Reports $15 Million Exit from MoonLake

On November 14, MPM BioImpact disclosed in a U.S. Securities and Exchange Commission filing that it completely divested its position in MoonLake Immunotherapeutics (NASDAQ: MLTX) during the third quarter, selling 313,571 shares. This move eliminated a stake that accounted for 2.6% of its assets under management and resulted in an estimated $14.8 million decrease based on average quarterly prices. Following this sale, MPM BioImpact’s top holdings were updated accordingly.

Want More Context? 🔎